Herbert Loong, MBBS, FASCO
@herbloong
Academic medical oncologist @ Hong Kong w/ interests in sarcoma medical oncology, thoracic oncology & phase 1 trials | Disclosures: bit.ly/3K6JvPf
ID: 787555563823443968
https://www.linkedin.com/in/herbert-loong-5a64147a 16-10-2016 07:27:33
3,3K Tweet
3,3K Followers
2,2K Following
Many thanks to my 🇸🇬 Duke-NUS Medical School #NCCS colleagues for kind invite & hospitality to discuss role #immunotherapy in #hereditarycancers at their #2nd #GrandRound together w/ Eileen Poon & Nurse Diana from their #genetics team. Excellent multidisciplinary discussions on #AYAOncology
Permission to post was granted 😊 by host. Early phase investigators participating in #foodeffect (or is it 🍷effect?) dose escalation cohort 😃. #Singapore 🇸🇬 #DavidTan Kai-Keen Shiu
A truly #international panel of experts! Register for the Desmoid Tumor Research Foundation International Research Workshop now! 😄
Glad to have had the opportunity to discuss updates in immunotherapy for cutaneous sarcomas with the great team of Sírio-Libanês Hospital (São Paulo), at their Sarcoma/Melanoma Grand Rounds. Always good to see familiar faces from 🇧🇷. Moffitt Cancer Center
Thrilled to take part in this webinar alongside esteemed moderators and panel members. Looking forward to sharing the challenges and lessons learned so far in Asia, the region with the highest burden of LCINS. ATS TO Assembly American Thoracic Society (ATS) Roger Kim, MD, MSCE, DAABIP Jeffrey Velotta MD FACS Lecia Sequist, MD, MPH
Listen to new data from the #ESMO24 congress as it appears in the field of oncogene-addicted #NSCLC with expert Dr Herbert Loong (Herbert Loong, MBBS, FASCO). Be ready and watch this space for a summary of the highlights during the congress #MedEd #Oncology
New article in press: A randomized study of 6 vs 3 years of adjuvant imatinib in patients with localized GIST at high risk of relapse. Jean-Yves Blay doi.org/10.1016/j.anno…